The startup develops ribonucleic acid products utilizing proprietary technologies such as mRNA de-immunization, expression boosting libraries, and novel lipid nanoparticle compositions for targeted delivery. This enables researchers to effectively integrate high-quality RNA into their projects, ensuring reliable performance across various applications in research and therapeutics.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective RNA-based therapeutics and vaccines requires overcoming challenges related to mRNA instability, immunogenicity, inefficient delivery, and scalability of manufacturing processes. Researchers and drug developers need reliable access to high-quality mRNA and lipid nanoparticle (LNP) formulation technologies to advance their programs from research to clinical applications.
Solution
RIBOPRO is a contract development and manufacturing organization (CDMO) specializing in mRNA and LNP technologies, offering a suite of services to support the development of RNA-based medicines. The company provides custom mRNA design and optimization, R&D- and GMP-grade manufacturing, and LNP formulation services using proprietary lipids and microfluidic technology. RIBOPRO's offerings include patented sequence-based de-immunization technology, in-house developed enzymes for high mRNA purity, and a novel core lipid system for targeted delivery and reduced liver bio-distribution. With a focus on quality, scalability, and innovation, RIBOPRO aims to accelerate the development of RNA therapies from research to clinical and commercial stages.
Target Audience
RIBOPRO serves biotech companies, pharmaceutical firms, and academic researchers involved in developing mRNA-based therapeutics and vaccines, from early-stage research to clinical trials and commercialization.
Features
- Custom mRNA synthesis with sequence optimization, including codon optimization and UTR selection
- Proprietary sequence-based de-immunization technology to minimize innate immune responses
- In-house developed enzymes with enhanced stability and fidelity for high-purity mRNA production
- GMP-ready and scalable manufacturing processes for seamless transition from R&D to clinical production
- LNP formulation services using proprietary ionizable lipids with low toxicity and immunogenicity
- Novel core lipid system for reduced liver bio-distribution and targeted delivery to other organs
- Analytical methods for quality control, including CGE, HPLC, ELISA, and Sanger sequencing
- Stability studies performed according to ICH standards